hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06283368, orgStudyIdInfo id: 2021/11-06, briefTitle: Red Blood Cell Distributions (RDW, RDW-CW) and Lymphocyte Monocyte Ratios (LMR) for the Malignant Thyroid Nodules, statusModule overallStatus: COMPLETED, startDateStruct date: 2016-01, primaryCompletionDateStruct date: 2021-01, completionDateStruct date: 2021-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Kahramanmaras Sutcu Imam University, class: OTHER, descriptionModule briefSummary: Thyroid surgery is the most common type of surgery among endocrine surgeries. This surgery is performed for patients with suspected malignancy, patients diagnosed with malignancy, and toxic nodular goiter. In addition to vocal cord injury, which is the most important complication of thyroid surgery, hypocalcemia due to hypoparathyroidism and surgical wound complications (such as hematoma, and fistula) can also be observed, and malignancy surgery increases the risk of recurrent laryngeal nerve injury. Therefore, it is important to differentiate these groups using non-invasive methods before surgery.Tumor-related inflammation is activated as a result of bone marrow and inflammation induced by malignancies. Insufficiently controlled or uncontrolled inflammatory activity may be responsible for malignant transformation. Lymphocyte monocyte ratio and red blood cell distribution are parameters (RDW, RDW-CW) previously studied in terms of cancers.Our aim in this study is to reveal the RDW, RDW-CW, and LMR calculated from complete blood count parameters in the preoperative period, as an indicator of malignant inflammatory response, in a non-invasive and inexpensive way before surgery or biopsy is performed to distinguish nodular goiter and thyroid malignancy., conditionsModule conditions: Thyroid Neoplasms Benign, conditions: Thyroid Nodule, conditions: Thyroid Cancer, conditions: Thyroid Diseases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 172, type: ACTUAL, armsInterventionsModule interventions name: Thyroidectomy, Bilaterally Total, interventions name: Thyroidectomy, Unilaterally Total, interventions name: Thyroidectomy, Complementary, interventions name: Thyroidectomy, Near Total, outcomesModule primaryOutcomes measure: Determining benign thyroid nodules, primaryOutcomes measure: Determining malignant thyroid nodules, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06283355, orgStudyIdInfo id: IRB00433691, briefTitle: Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2025-06-01, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Johns Hopkins University, class: OTHER, descriptionModule briefSummary: This study aims to determine whether a parent-to-child nasal microbiota transplant (NMT) can seed and engraft parental organisms into the neonatal microbiome and increase the neonatal microbiome diversity., conditionsModule conditions: Staphylococcus Aureus, conditions: Microbial Colonization, conditions: Neonatal Infection, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 175, type: ESTIMATED, armsInterventionsModule interventions name: Nasal Microbiota Transplant (NMT), interventions name: Placebo, outcomesModule primaryOutcomes measure: Neonatal nasal microbiome diversity after intervention, eligibilityModule sex: ALL, minimumAge: 0 Years, maximumAge: 60 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Johns Hopkins University, city: Baltimore, state: Maryland, zip: 21287, country: United States, contacts name: Danielle Koontz, role: CONTACT, phone: 443-287-9040, email: dkoontz1@jhmi.edu, contacts name: Aaron Milstone, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.29038, lon: -76.61219, hasResults: False
protocolSection identificationModule nctId: NCT06283342, orgStudyIdInfo id: Konya Pediatric Hematology, briefTitle: Prophylactic Iron and Nutrition in Preventing Infant Iron Deficiency, statusModule overallStatus: COMPLETED, startDateStruct date: 2018-01-01, primaryCompletionDateStruct date: 2019-01-01, completionDateStruct date: 2019-02-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Konya Meram State Hospital, class: OTHER, descriptionModule briefSummary: This study aimed to reveal the effects of prophylactic iron preparations, adequate breast milk intake, and iron-rich supplementary food intake in the prevention of IDA (iron deficiency anemia) and ID (iron deficiency) in infancy., conditionsModule conditions: Iron Deficiency Anemia in Childbirth, conditions: Infant Nutrition Disorders, conditions: Iron Deficiencies, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 2, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Ferritine level, secondaryOutcomes measure: Hemoglobin level, secondaryOutcomes measure: Prophylactic iron use rate, secondaryOutcomes measure: Iron-sufficient supplementary food intake rate of babies, secondaryOutcomes measure: Breast milk usage rate, eligibilityModule sex: ALL, minimumAge: 6 Months, maximumAge: 24 Months, stdAges: CHILD, contactsLocationsModule locations facility: Konya Training and Research Hospital, city: Konya, zip: 42090, country: Turkey, geoPoint lat: 37.87135, lon: 32.48464, hasResults: False
protocolSection identificationModule nctId: NCT06283329, orgStudyIdInfo id: echographic VC curarization, briefTitle: Residual Vocal Cords Curarization Correlation Between Clinical and Ultrasound Endpoints, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-12-01, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: General Administration of Military Health, Tunisia, class: NETWORK, descriptionModule briefSummary: Through recent studies residual curarization (RC) remains frequent but serious event, that could be easily avoided in the presence of a paraclinical monitoring and by antagonization of curares. However, conventional monitors focus only on peripheral muscles, whereas ultrasonography allows direct visualization of laryngeal muscles, particularly the vocal cords, which are directly influenced by neuromuscular blocking agents. The aim of the study was to evaluate the ultrasound mobility of the vocal cords after awakening and extubation of general anesthesia compared to their preoperative mobility and its correlation with clinical and paraclinical diagnostic criteria (DG) for RC., conditionsModule conditions: Residual Curarization, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 70, type: ACTUAL, armsInterventionsModule interventions name: vocal cords echography, outcomesModule primaryOutcomes measure: Echographic mobility of vocal cords at different times in post extubation, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Elaskri Haythem, city: Tunis, zip: 1008, country: Tunisia, geoPoint lat: 36.81897, lon: 10.16579, hasResults: False
protocolSection identificationModule nctId: NCT06283316, orgStudyIdInfo id: 11347, briefTitle: Systemic Treatments for Alopecia Areata Registry, acronym: STA2R, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-17, primaryCompletionDateStruct date: 2099-12-31, completionDateStruct date: 2099-12-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Erasmus Medical Center, class: OTHER, descriptionModule briefSummary: A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes., conditionsModule conditions: Alopecia Areata, conditions: Alopecia Totalis, conditions: Alopecia Universalis, conditions: Hair Loss, conditions: Hair Diseases, conditions: Alopecia, conditions: Alopecia Drugs, conditions: Autoimmune Diseases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 10000, type: ESTIMATED, outcomesModule primaryOutcomes measure: Effectiveness of systemic treatments, primaryOutcomes measure: Safety of systemic treatments, secondaryOutcomes measure: Epidemiological data, secondaryOutcomes measure: Physician Reported - Severity of Alopecia Tool (SALT Score), secondaryOutcomes measure: Dermatology Life Quality Index (DLQI, 10 items), secondaryOutcomes measure: Alopecia Areata Symptom Impact Scale (AASIS, 13 items), eligibilityModule sex: ALL, minimumAge: 16 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Erasmus University Medical Center, status: RECRUITING, city: Rotterdam, country: Netherlands, contacts name: DirkJan Hijnen, MD, PhD, role: CONTACT, phone: 0031 10 704 01 10, email: d.hijnen@erasmusmc.nl, geoPoint lat: 51.9225, lon: 4.47917, hasResults: False
protocolSection identificationModule nctId: NCT06283303, orgStudyIdInfo id: MVR-T3011-HAI-01, briefTitle: A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-02, primaryCompletionDateStruct date: 2025-11-30, completionDateStruct date: 2025-11-30, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: China Medical University, China, class: OTHER, collaborators name: Immvira Co., Limited, descriptionModule briefSummary: This is a phase I, open-label clinical study of T3011 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer., conditionsModule conditions: Colorectal Cancer Metastatic, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 8, type: ESTIMATED, armsInterventionsModule interventions name: T3011 hepatic artery infusion, interventions name: toripalimab, interventions name: regorafenib, outcomesModule primaryOutcomes measure: Treatment Emergent Adverse Event（TEAE）, secondaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Progression-free survival (PFS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06283277, orgStudyIdInfo id: fetal macrosomia, briefTitle: Fetal Clavicular Measurement to Predict Fetal Macrosomia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2027-04-30, completionDateStruct date: 2027-10-30, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Macrosomia is associated with increased risks for both the mother and the baby, including complications during delivery, injuries, and even death. The accurate diagnosis of macrosomia is often difficult before birth. There are a number of factors that can increase the risk of macrosomia, such as maternal obesity, diabetes, and excessive weight gain during pregnancy. There are also a number of different techniques that can be used to try to predict macrosomia, but none of them are perfect.The aim of this study is to evaluate sensitivity of measuring fetal clavicle length in third trimester compared with biacromial diameter and Hadlock formula IV for prediction of fetal macrosomia., conditionsModule conditions: Macrosomia, Fetal, conditions: Large for Gestational Age, conditions: Shoulder Dystocia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 240, type: ESTIMATED, armsInterventionsModule interventions name: Obstetric Ultrasound, outcomesModule primaryOutcomes measure: Third trimester clavicle length measurement, secondaryOutcomes measure: Establish the relationship between third-trimester clavicle length and shoulder dystocia, secondaryOutcomes measure: Mode of delivery, secondaryOutcomes measure: Gestational age at the time of delivery., secondaryOutcomes measure: Neonatal Apgar score., secondaryOutcomes measure: Neonatal bi-acromial diameter, secondaryOutcomes measure: Neonatal birth weight, secondaryOutcomes measure: Neonatal need for NICU, secondaryOutcomes measure: Neonatal actual clavicle length, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06283264, orgStudyIdInfo id: Coeliac Disease in type2 DM, briefTitle: Assessment of Coeliac Disease in Patients With Type 2 Diabetes, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2026-12-01, completionDateStruct date: 2026-12-30, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: This study aims to screen and diagnose coeliac disease in patients with type 2 diabetes and monitor the effect of gluten-free diet on the metabolic status, conditionsModule conditions: Celiac Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 100, type: ESTIMATED, outcomesModule primaryOutcomes measure: 1-Prevalence of coeliac disease among diabetic type 2 patient 2-its effect on glycemic control, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06283251, orgStudyIdInfo id: 23-590, briefTitle: PediRISE Feasibility, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Dana-Farber Cancer Institute, class: OTHER, collaborators name: American Cancer Society, Inc., collaborators name: Children's Cancer Research Fund, descriptionModule briefSummary: The goal of this research study is to learn whether investigators can successfully give the PediRISE program to families-in other words, whether most families are interested in participating in a study about the PediRISE program, including a 50-50 chance of receiving standard usual care, and a 50-50 chance of receiving the PediRISE support program.The names of the study groups in this research study are:* PediRISE Program Group* Usual Care Group, conditionsModule conditions: Pediatric Cancer, conditions: Financial Stress, conditions: Financial Hardship, conditions: Disparities, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: PediRISE Resource Program, outcomesModule primaryOutcomes measure: Rate of Participant Consent, primaryOutcomes measure: 6-Month Follow Up Rate for PediRISE Program Group, primaryOutcomes measure: 6-Month Follow Up Rate for Usual Care Group, eligibilityModule sex: ALL, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Boston Children's Hospital, city: Boston, state: Massachusetts, zip: 02215, country: United States, contacts name: Kira Bona, MD, MPH, role: CONTACT, phone: 617-632-4688, email: Kira_Bona@dfci.harvard.edu, contacts name: Kira Bona, MD, MPH, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.35843, lon: -71.05977, locations facility: Dana Farber Cancer Institute, city: Boston, state: Massachusetts, zip: 02215, country: United States, contacts name: Kira Bona, MD, MPH, role: CONTACT, phone: 617-632-4688, email: Kira_Bona@dfci.harvard.edu, contacts name: Kira Bona, MD, MPH, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06283238, orgStudyIdInfo id: Pro00115121, briefTitle: Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-25, primaryCompletionDateStruct date: 2026-03-25, completionDateStruct date: 2027-03-25, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Duke University, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to examine genetic changes that may contribute to immunotherapy resistance in gastroesophageal cancer. This information can potentially lead to the identification of new immunotherapeutic targets as well as improve the ability to identify those patients more likely to respond to immunotherapy.This study does not include any treatment or investigational drugs.Participants will be asked:* to enroll before beginning standard care of treatment for their cancer* for blood, archived tumor tissue, and fresh tumor tissue Researchers will compare participants who are not getting immunotherapy to identify potential differences in expression levels of a gene., conditionsModule conditions: GastroEsophageal Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: Immune checkpoint inhibitor (ICI) or chemotherapy alone, outcomesModule primaryOutcomes measure: Number of participants with Complete Response (CR), primaryOutcomes measure: Number of participants with Partial Response (PR), primaryOutcomes measure: Number of participants with Stable Disease, primaryOutcomes measure: Number of participants with Progressive Disease, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Duke University, city: Durham, state: North Carolina, zip: 27710, country: United States, geoPoint lat: 35.99403, lon: -78.89862, hasResults: False
protocolSection identificationModule nctId: NCT06283225, orgStudyIdInfo id: RCT004_PilotPia, briefTitle: Pilot Study to Investigate the Effect of a Dysmenorrhoea App, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Endo Health GmbH, class: INDUSTRY, descriptionModule briefSummary: The pilot study investigates the influence of a dysmenorrhoea app on the quality of life and symptoms of women with dysmenorrhoea. The intervention group can use the app over the study period of 12 weeks in addition to usual care, while the control group only receives the usual standard care. The aim is to evaluate the effectiveness of the app and to gain insights for the design of future studies. The study is expected to last seven months and include 100-200 participants., conditionsModule conditions: Dysmenorrhea, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: intervention group and control group, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Pia-App, outcomesModule primaryOutcomes measure: Dysmenorrhea Symptom Interference Scale (DSI), primaryOutcomes measure: Moos Menstrual Distress Questionnaire, Form C (MDQ), primaryOutcomes measure: Visual analog scale (VAS), primaryOutcomes measure: Depression Anxiety Stress Scale mit 21 Items (DASS-21), primaryOutcomes measure: German Version of Pain Self-Efficacy Questionnaire (FESS), primaryOutcomes measure: Fatigue Severity Scale (FSS), primaryOutcomes measure: Pain Disability Index (PDI), eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False